{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:31:25Z","timestamp":1788877885744,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Although Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccines have been used in the U.S. for decades and have extensive safety records, a comprehensive post-marketing assessment for all available types is still needed. This study leveraged the Vaccine Adverse Event Reporting System (VAERS) database to evaluate adverse events following immunization (AEFI) and analyze potential associations with vaccine administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted all reports of adverse events (AEs) following DTaP vaccination from the VAERS database for the period 1990 to May 2025. Our analysis included descriptive statistics to summarize patient demographics and clinical features, and disproportionality methods to identify potential safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, the VAERS database documented 57,341 children under 7 years who received DTaP vaccines, corresponding to 57,368 administered doses and 193,955 adverse event (AE) reports. AE reporting was more frequent in males (52.46%) than females (45.07%), with more than half of the cases (50.44%) involving children under 2 years old. The most common clinical outcomes were recovery (62.53%) and hospitalization (10.29%). Most AEs (89.61%) occurred within 0\u201330 days after vaccination, with a median onset time of 1.0 days. Infanrix (37.95%) and Daptacel (25.04%) were the most frequently reported vaccine types. Disproportionality analysis detected 158 positive AE signals across 24 system organ classes (SOCs). Among all SAEs, pyrexia (ROR = 1.01) was the most frequently reported, followed by convulsion (ROR = 1.82) and vomiting (ROR = 1.05). The most common signals for non-SAEs included injection site erythema (ROR = 3.79), injection site swelling (ROR = 3.00), and erythema (ROR = 3.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This post-marketing surveillance indicates that most reported AEs were non-serious and occurred within 30 days following vaccination. These findings support the known safety profile of DTaP vaccines and highlight identifiable timing patterns of AEs, which may help inform monitoring strategies and benefit-risk assessments after immunization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1733777","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:31:56Z","timestamp":1770013916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Diphtheria-tetanus-acellular pertussis vaccine safety in children under 7 years: a post-marketing analysis of the U.S. vaccine adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Meishen","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linshu","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hening","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central Hospital of Dalian University of Technology","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinkuo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central Hospital of Dalian University of Technology","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e643","DOI":"10.1542\/peds.2004-2185","article-title":"Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia","volume":"115","author":"Brotherton","year":"2005","journal-title":"Pediatrics."},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"B4","unstructured":"Pertussis Vaccination: Acellular Pertussis Vaccine for Reinforcing and Booster Use \u2013 Supplementary ACIP Statement Recommendations of the Immunization Practices Advisory Committee\n          \n          1992"},{"key":"B5","unstructured":"Food and Drug Administration Approval of a Second Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine\n          \n          1992"},{"key":"B6","unstructured":"Notice to Readers Food and Drug Administration Approval of an Acellular Pertussis Vaccine for the Initial Four Doses of the Diphtheria, Tetanus, and Pertussis Vaccination Series\n          \n          1996"},{"key":"B7","unstructured":"Notice to Readers Recommended Childhood Immunization Schedule \u2013 United States\n          \n          1997"},{"key":"B8","unstructured":"2022 Final Pertussis Surveillance Report\n          \n          2024"},{"key":"B9","unstructured":"2023 Final Pertussis Surveillance Report\n          \n          2025"},{"key":"B10","unstructured":"Manual for the surveillance of vaccine-preventable diseases\n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/0264-410x(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.vaccine.2005.11.057","article-title":"Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults","volume":"24","author":"Cook","year":"2006","journal-title":"Vaccine."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178077","article-title":"Post-marketing safety profile of Ertugliflozin: Insights from a real-world pharmacovigilance analysis based on the FAERS database","volume":"1005","author":"Dong","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pediatrneurol.2017.08.005","article-title":"Vaccine safety datalink. Febrile seizure risk after vaccination in children one to five months of age","volume":"76","author":"Duffy","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2571277","article-title":"Acceptability of patient-centered digital vaccine safety monitoring: A Canadian Immunization Research Network study","volume":"21","author":"Ellis-Legault","year":"2025","journal-title":"Hum. Vaccin Immunother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jnnp.71.5.638","article-title":"A magnetic resonance study of complicated early childhood convulsion","volume":"71","author":"Gr\u00fcnewald","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","article-title":"Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance","volume":"39","author":"Heo","year":"2020","journal-title":"Stat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1586\/14760584.2014.883285","article-title":"Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature","volume":"13","author":"Herzog","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.15585\/mmwr.mm6740a4","article-title":"Vaccination Coverage among children aged 19\u201335 months - United States, 2017","volume":"67","author":"Hill","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/pds.4141","article-title":"Vaccination and unexplained sudden death risk in Taiwanese infants","volume":"26","author":"Huang","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B22","volume-title":"Immunization safety review: vaccinations and sudden unexpected death in infancy","author":"Stratton","year":"2003"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.4161\/hv.29576","article-title":"Licensed pertussis vaccines in the United States","volume":"10","author":"Klein","year":"2014","journal-title":"His Curr. State Hum. Vaccin Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10030472","article-title":"Immunogenicity and safety of childhood combination vaccines: A systematic review and meta-analysis","volume":"10","author":"Liu","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.vaccine.2021.01.009","article-title":"DTaP combination vaccine use and adherence: A retrospective cohort study","volume":"39","author":"Loiacono","year":"2021","journal-title":"Vaccine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/INF.0000000000003609","article-title":"Timing of Monovalent vaccine administration in infants receiving DTaP-based combination vaccines in the United States","volume":"41","author":"Marshall","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.4161\/21645515.2014.985506","article-title":"Mixing of diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in a population of children in managed care","volume":"11","author":"Masseria","year":"2015","journal-title":"Hum. Vaccin Immunother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/14760584.2019.1676154","article-title":"Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention","volume":"18","author":"Moro","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e20174171","DOI":"10.1542\/peds.2017-4171","article-title":"Safety surveillance of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines","volume":"142","author":"Moro","year":"2018","journal-title":"Pediatrics."},{"key":"B33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011","volume":"30","author":"Tse","year":"2012","journal-title":"Vaccine."},{"key":"B35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.7883\/yoken.JJID.2020.947","article-title":"Safety of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine in adults in Japan","volume":"74","author":"Ujiie","year":"2021","journal-title":"Jpn J. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.vaccine.2006.07.027","article-title":"Sudden infant death syndrome: no increased risk after immunisation","volume":"25","author":"Vennemann","year":"2007","journal-title":"Vaccine."},{"key":"B37","unstructured":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification\n          \n          2021"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1733777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:29:15Z","timestamp":1771925355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1733777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":37,"alternative-id":["10.3389\/fcimb.2026.1733777"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1733777","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"1733777"}}